28
Pharma & HealthcareAvoid
ITI Pharma And Healthcare
ITI · Direct–Growth · rank #17 of 19 by Smart Score
Data updated
Trailing returns
1 Year
17.1%
+16.3% vs index
3 Years
19.9%
+8.3% vs index
5 Years
15.6%
+5.5% vs index
Since launch
15.4%
Year-by-year performance
2022
-6.7%-10.5% vs index
2023
+34.4%+7.9% vs index
2024
+44.0%+28.3% vs index
2025
-8.2%-15.9% vs index
2026
+20.6%+19.7% vs index
Why this score
ITI Pharma And Healthcare scores 28/100 — #17 of 19 Pharma & Healthcare fund (Avoid). It stands out for expense ratio — beating 86% of peers on expense ratio. The main drag is its 3y return (better than only 21% of peers).
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
3Y return19.86% · 21st percentile in category
5Y return15.60% · 25th percentile in category
Volatility16.53 · 9th percentile in category
Alpha0.31 · 3rd percentile in category
Expense ratio0.89% · 86th percentile in category
Fund size266.74 Cr · 13th percentile in category
Top holdings
1.Sun Pharmaceutical Industries Ltd11.67%
2.Divi's Laboratories Ltd9.98%
3.Apollo Hospitals Enterprise Ltd5.62%
4.Dr. Reddy's Laboratories Ltd5.23%
5.Torrent Pharmaceuticals Ltd4.58%
37 disclosed equity positions · portfolio as of Oct 2026 · weights are % of total corpus.